We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · September 07, 2020

Effect of Dapagliflozin According to Baseline Systolic Blood Pressure in DAPA-HF

European Heart Journal

 

Additional Info

European Heart Journal
Effect of Dapagliflozin According to Baseline Systolic Blood Pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial (DAPA-HF)
Eur Heart J 2020 Aug 21;[EPub Ahead of Print], M Serenelli, M Böhm, SE Inzucchi, L Køber, MN Kosiborod, FA Martinez, P Ponikowski, MS Sabatine, SD Solomon, DL DeMets, O Bengtsson, M Sjöstrand, AM Langkilde, IS Anand, CE Chiang, VK Chopra, RA de Boer, M Diez, A Dukát, J Ge, JG Howlett, T Katova, M Kitakaze, CEA Ljungman, S Verma, KF Docherty, PS Jhund, JJV McMurray

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading